Over 50 patients are currently enrolled in our pivotal Phase 3 Clinical Trial of EMD-RX5, with 83 patients awaiting dosing & another 1700+ successfully pre-screened.

2 more trial sites will also activate this week, meaning all 9 clinical trial sites will have commenced dosing, and the trial is expected to conclude in July 2023.

Read the full update: Strong Recruitment for EMD-RX5 Phase 3 Trial | Emyria Investor Hub